Index RUT
P/E -
EPS (ttm) -2.41
Insider Own 9.95%
Shs Outstand 63.76M
Perf Week 8.05%
Market Cap 3.17B
Forward P/E -
EPS next Y -3.32
Insider Trans -7.98%
Shs Float 57.41M
Perf Month 2.55%
Income -157.85M
PEG -
EPS next Q -0.84
Inst Own 97.17%
Short Float 16.29%
Perf Quarter 55.64%
Sales 88.55M
P/S 35.85
EPS this Y -16.68%
Inst Trans 3.48%
Short Ratio 16.58
Perf Half Y 21.97%
Book/sh 11.12
P/B 4.48
EPS next Y -13.00%
ROA -22.42%
Short Interest 9.35M
Perf Year 185.99%
Cash/sh 8.00
P/C 6.23
EPS next 5Y 1.90%
ROE -28.18%
52W Range 9.60 - 50.69
Perf YTD 95.56%
Dividend Est. -
P/FCF -
EPS past 5Y -39.18%
ROI -20.75%
52W High -1.78%
Beta 2.22
Dividend TTM -
Quick Ratio 8.45
Sales past 5Y 241.22%
Gross Margin 94.17%
52W Low 418.65%
ATR (14) 2.50
Dividend Ex-Date -
Current Ratio 8.45
EPS Y/Y TTM 12.58%
Oper. Margin -204.01%
RSI (14) 60.95
Volatility 5.59% 4.90%
Employees 187
Debt/Eq 0.13
Sales Y/Y TTM 71.38%
Profit Margin -178.27%
Recom 1.47
Target Price 55.38
Option/Short Yes / Yes
LT Debt/Eq 0.11
EPS Q/Q 13.45%
Payout -
Rel Volume 2.21
Prev Close 49.03
Sales Surprise 104.31%
EPS Surprise 14.87%
Sales Q/Q 55.33%
Earnings Aug 07 BMO
Avg Volume 563.89K
Price 49.79
SMA20 5.72%
SMA50 10.77%
SMA200 36.37%
Trades
Volume 1,245,900
Change 1.55%
Date
Action
Analyst
Rating Change
Price Target Change
Sep-09-24 Resumed
Leerink Partners
Outperform
$60
Aug-26-24 Upgrade
Wolfe Research
Peer Perform → Outperform
$65
Apr-22-24 Initiated
Oppenheimer
Outperform
$53
Feb-15-24 Initiated
Wolfe Research
Peer Perform
Jan-04-24 Upgrade
JP Morgan
Neutral → Overweight
Jan-03-24 Downgrade
BofA Securities
Buy → Neutral
$45 → $30
Dec-19-23 Downgrade
Wells Fargo
Overweight → Equal Weight
$26
Jun-30-23 Initiated
Truist
Buy
$50
May-05-23 Upgrade
Raymond James
Mkt Perform → Outperform
Dec-06-22 Downgrade
Credit Suisse
Outperform → Neutral
$47 → $32
Nov-08-22 Initiated
Raymond James
Mkt Perform
Aug-15-22 Initiated
Jefferies
Buy
$40
Aug-03-22 Initiated
Goldman
Buy
$40
Jul-20-22 Initiated
SVB Leerink
Mkt Perform
$26
Apr-28-22 Initiated
Credit Suisse
Outperform
$63
Mar-10-22 Initiated
JP Morgan
Neutral
$44
Feb-10-22 Initiated
Wells Fargo
Overweight
$62
Sep-30-21 Initiated
Stifel
Buy
$80
Sep-30-21 Initiated
B. Riley Securities
Neutral
$67
Sep-10-21 Downgrade
BofA Securities
Buy → Neutral
$65 → $80
Show Previous Ratings
Sep-06-24 11:31AM
Aug-28-24 07:00AM
Aug-21-24 11:15AM
Aug-20-24 01:02PM
07:44AM
10:45PM
Loading…
Aug-19-24 10:45PM
04:01PM
Aug-08-24 09:55AM
Aug-07-24 08:10AM
07:00AM
Jul-31-24 07:00AM
Jul-10-24 08:10AM
Jul-09-24 01:30PM
12:22PM
10:44AM
09:59AM
Loading…
09:59AM
07:00AM
Jul-08-24 04:05PM
Jun-20-24 08:45AM
Jun-14-24 07:00AM
Jun-01-24 08:00AM
May-29-24 07:00AM
May-23-24 05:00PM
May-22-24 11:20AM
May-14-24 10:00AM
May-08-24 07:00AM
May-03-24 12:23PM
09:57AM
09:55AM
08:44AM
03:19AM
Loading…
03:19AM
May-02-24 12:18PM
11:57AM
07:00AM
Apr-25-24 10:02AM
09:20AM
07:00AM
Apr-08-24 07:00AM
Mar-08-24 10:00AM
Mar-04-24 11:27PM
Feb-28-24 07:00AM
Feb-23-24 11:59AM
Feb-22-24 11:24PM
(Thomson Reuters StreetEvents)
07:35AM
07:00AM
Feb-21-24 11:52PM
Feb-15-24 10:00AM
07:00AM
Feb-10-24 02:56AM
Jan-31-24 07:00AM
Jan-24-24 12:20AM
Jan-17-24 08:00AM
Jan-09-24 09:17AM
09:15AM
Jan-05-24 04:03PM
(Investor's Business Daily)
06:00AM
Jan-04-24 04:01PM
07:00AM
Jan-02-24 07:00AM
Dec-22-23 10:45AM
Dec-18-23 02:58PM
Dec-13-23 07:00AM
Dec-10-23 09:00PM
Dec-08-23 11:13AM
Dec-07-23 07:00AM
Nov-13-23 11:00AM
Nov-07-23 09:05AM
Nov-05-23 02:38PM
Nov-02-23 09:00AM
08:43AM
07:00AM
Nov-01-23 07:00AM
Oct-27-23 07:00AM
Oct-26-23 10:02AM
07:00AM
Oct-19-23 09:35AM
Oct-18-23 09:35AM
Oct-16-23 07:00AM
Oct-04-23 06:23AM
Oct-03-23 04:48PM
Sep-18-23 07:00AM
Aug-28-23 07:00AM
Aug-03-23 08:25AM
07:00AM
Jul-28-23 03:57PM
Jul-27-23 07:00AM
Jul-09-23 09:09AM
Jun-22-23 08:30AM
Jun-14-23 02:30AM
Jun-09-23 06:00PM
03:00AM
Jun-01-23 07:00AM
May-29-23 12:24PM
May-22-23 07:00AM
May-19-23 07:00AM
May-18-23 07:00AM
May-14-23 02:57PM
May-09-23 03:15PM
May-04-23 08:25AM
07:00AM
Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Esposito Pamela Director Sep 17 '24 Option Exercise 23.86 13,500 322,075 13,500 Sep 17 06:20 PM Esposito Pamela Director Sep 17 '24 Sale 48.28 13,500 651,766 0 Sep 17 06:20 PM PAMELA ESPOSITO Director Sep 17 '24 Proposed Sale 48.48 13,500 654,480 Sep 17 04:40 PM Albers Jeffrey W. Director Aug 26 '24 Option Exercise 10.34 5,000 51,700 5,000 Aug 26 06:31 PM Albers Jeffrey W. Director Aug 26 '24 Sale 49.10 5,000 245,508 0 Aug 26 06:31 PM JOANNA HOROBIN Director Aug 26 '24 Proposed Sale 49.16 12,000 589,896 Aug 26 04:32 PM JEFFREY ALBERS Director Aug 26 '24 Proposed Sale 47.78 5,000 238,900 Aug 26 04:25 PM BAKER BROS. ADVISORS LP Director Aug 20 '24 Buy 46.41 1 46 5,516,986 Aug 22 04:03 PM Gollob Jared Chief Medical Officer Jul 16 '24 Option Exercise 2.08 23,145 48,142 118,885 Jul 16 06:00 PM Gollob Jared Chief Medical Officer Jul 15 '24 Option Exercise 2.08 16,455 34,226 112,195 Jul 16 06:00 PM Gollob Jared Chief Medical Officer Jul 16 '24 Sale 45.81 23,145 1,060,218 95,470 Jul 16 06:00 PM Gollob Jared Chief Medical Officer Jul 15 '24 Sale 45.15 16,455 742,925 95,740 Jul 16 06:00 PM Booth Bruce Director Jul 09 '24 Sale 38.21 453,960 17,346,919 723,246 Jul 09 05:15 PM Mainolfi Nello Chief Executive Officer Jul 01 '24 Option Exercise 5.33 18,773 100,060 649,959 Jul 01 04:30 PM Jacobs Bruce N. Chief Financial Officer Jun 27 '24 Option Exercise 2.08 25,000 52,000 168,554 Jun 28 08:30 AM Mainolfi Nello Chief Executive Officer Jun 18 '24 Option Exercise 2.08 14,413 29,979 631,186 Jun 20 08:30 AM Booth Bruce Director Jun 12 '24 Sale 35.45 16,740 593,378 803,792 Jun 14 06:01 PM Booth Bruce Director Jun 13 '24 Sale 34.98 10,200 356,796 802,022 Jun 14 06:01 PM Horobin Joanna Director Jun 07 '24 Option Exercise 2.08 8,500 17,680 8,500 Jun 07 06:36 PM Horobin Joanna Director Jun 07 '24 Sale 32.99 8,500 280,400 0 Jun 07 06:36 PM Chadwick Jeremy G Chief Operating Officer May 23 '24 Sale 34.99 2,575 90,105 44,183 May 23 04:10 PM Booth Bruce Director Mar 15 '24 Sale 40.46 71,764 2,903,336 806,697 Mar 15 07:23 PM Booth Bruce Director Mar 14 '24 Sale 39.98 55,779 2,229,927 819,151 Mar 15 07:23 PM Atlas Venture Fund X, L.P. 10% Owner Mar 12 '24 Sale 41.98 134,647 5,652,072 4,791,165 Mar 13 07:53 PM Atlas Venture Fund X, L.P. 10% Owner Mar 13 '24 Sale 42.23 115,090 4,859,993 4,676,075 Mar 13 07:53 PM Atlas Venture Fund X, L.P. 10% Owner Mar 11 '24 Sale 42.85 42,302 1,812,586 4,925,812 Mar 13 07:53 PM Atlas Venture Fund X, L.P. 10% Owner Mar 12 '24 Sale 41.98 28,271 1,186,741 852,995 Mar 13 07:53 PM Atlas Venture Fund X, L.P. 10% Owner Mar 13 '24 Sale 42.23 24,165 1,020,422 828,830 Mar 13 07:53 PM Atlas Venture Fund X, L.P. 10% Owner Mar 11 '24 Sale 42.85 8,882 380,562 881,266 Mar 13 07:53 PM Booth Bruce Director Mar 12 '24 Sale 41.98 162,918 6,838,813 852,995 Mar 13 07:52 PM Booth Bruce Director Mar 13 '24 Sale 42.23 139,255 5,880,415 828,830 Mar 13 07:52 PM Booth Bruce Director Mar 11 '24 Sale 42.85 51,184 2,193,148 881,266 Mar 13 07:52 PM Gollob Jared Chief Medical Officer Mar 04 '24 Sale 41.86 3,344 139,967 95,740 Mar 04 06:21 PM Jacobs Bruce N. Chief Financial Officer Mar 04 '24 Sale 41.86 3,934 164,664 142,351 Mar 04 06:12 PM Albers Jeffrey W. Director Feb 21 '24 Option Exercise 10.34 4,385 45,341 4,385 Feb 21 06:46 PM Albers Jeffrey W. Director Feb 20 '24 Option Exercise 10.34 615 6,359 615 Feb 21 06:46 PM Albers Jeffrey W. Director Feb 21 '24 Sale 39.05 4,385 171,227 0 Feb 21 06:46 PM Albers Jeffrey W. Director Feb 20 '24 Sale 39.07 615 24,031 0 Feb 21 06:46 PM Gollob Jared Chief Medical Officer Feb 09 '24 Option Exercise 2.08 46,137 95,965 120,846 Feb 09 07:47 PM Gollob Jared Chief Medical Officer Feb 09 '24 Sale 35.50 46,137 1,638,071 74,709 Feb 09 07:47 PM Albers Jeffrey W. Director Jan 23 '24 Option Exercise 10.34 10,000 103,400 10,000 Jan 23 07:37 PM Albers Jeffrey W. Director Jan 23 '24 Sale 30.05 10,000 300,470 0 Jan 23 07:37 PM Chiniara Ellen Chief Legal Officer Jan 04 '24 Sale 22.58 3,295 74,416 34,205 Jan 05 05:15 PM Mainolfi Nello Chief Executive Officer Jan 02 '24 Option Exercise 2.08 9,000 18,720 615,570 Jan 02 05:43 PM BVF PARTNERS L P/IL Director Nov 03 '23 Buy 14.07 197,699 2,781,407 2,656,191 Nov 06 06:07 PM BVF PARTNERS L P/IL Director Nov 02 '23 Buy 11.64 216,406 2,519,918 2,552,306 Nov 06 06:07 PM Mainolfi Nello Chief Executive Officer Nov 03 '23 Option Exercise 2.08 20,000 41,600 606,570 Nov 06 06:00 PM
Index RUT
P/E -
EPS (ttm) -3.34
Insider Own 23.22%
Shs Outstand 61.42M
Perf Week -1.98%
Market Cap 745.37M
Forward P/E -
EPS next Y -2.75
Insider Trans -0.77%
Shs Float 52.46M
Perf Month 6.23%
Income -220.01M
PEG -
EPS next Q -0.83
Inst Own 87.76%
Short Float 9.96%
Perf Quarter 28.35%
Sales 0.00M
P/S -
EPS this Y 1.90%
Inst Trans -0.71%
Short Ratio 6.39
Perf Half Y 33.05%
Book/sh 6.24
P/B 1.75
EPS next Y 13.62%
ROA -38.64%
Short Interest 5.23M
Perf Year -34.36%
Cash/sh 6.87
P/C 1.59
EPS next 5Y -
ROE -46.79%
52W Range 4.92 - 17.89
Perf YTD 29.42%
Dividend Est. -
P/FCF -
EPS past 5Y -19.52%
ROI -44.13%
52W High -39.02%
Beta 1.21
Dividend TTM -
Quick Ratio 13.46
Sales past 5Y 0.00%
Gross Margin -
52W Low 121.75%
ATR (14) 0.67
Dividend Ex-Date -
Current Ratio 13.46
EPS Y/Y TTM -8.24%
Oper. Margin 0.00%
RSI (14) 55.53
Volatility 7.13% 6.49%
Employees 331
Debt/Eq 0.18
Sales Y/Y TTM -
Profit Margin -
Recom 1.10
Target Price 15.00
Option/Short Yes / Yes
LT Debt/Eq 0.17
EPS Q/Q -4.08%
Payout -
Rel Volume 4.56
Prev Close 11.23
Sales Surprise -
EPS Surprise 8.98%
Sales Q/Q -
Earnings Aug 08 BMO
Avg Volume 817.51K
Price 10.91
SMA20 3.68%
SMA50 6.33%
SMA200 31.17%
Trades
Volume 3,730,522
Change -2.85%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-28-24 Initiated
ROTH MKM
Buy
$17
Apr-17-23 Resumed
Piper Sandler
Overweight
$44
Nov-19-21 Initiated
Piper Sandler
Overweight
$52
Oct-15-21 Resumed
BTIG Research
Buy
$60
Nov-17-20 Initiated
BTIG Research
Buy
$60
Nov-02-20 Initiated
Jefferies
Buy
$67
Oct-15-20 Upgrade
H.C. Wainwright
Neutral → Buy
$25 → $54
Jul-01-20 Downgrade
H.C. Wainwright
Buy → Neutral
$25
May-05-20 Initiated
Barclays
Overweight
$21
Sep-04-19 Initiated
ROTH Capital
Buy
$20
Jul-23-19 Initiated
Chardan Capital Markets
Buy
$28
Jul-12-19 Upgrade
JP Morgan
Neutral → Overweight
$27 → $26
Jul-08-19 Initiated
H.C. Wainwright
Buy
$26
Apr-25-19 Initiated
Wedbush
Outperform
$24
Jan-23-19 Downgrade
JP Morgan
Overweight → Neutral
Aug-14-18 Initiated
Leerink Partners
Outperform
$25
Aug-14-18 Initiated
JP Morgan
Overweight
$26
Show Previous Ratings
Sep-15-24 09:45AM
Sep-09-24 08:00AM
Sep-05-24 08:00AM
Aug-22-24 08:00AM
Aug-14-24 04:33PM
(Pharmaceutical Technology)
08:00AM
Loading…
Aug-13-24 08:00AM
Aug-08-24 08:00AM
Jul-30-24 04:01PM
Jun-13-24 08:30AM
Jun-07-24 09:03AM
08:00AM
Jun-06-24 12:16PM
07:00AM
Jun-03-24 08:00AM
May-23-24 05:00PM
01:53PM
Loading…
May-16-24 01:53PM
08:00AM
Apr-07-24 05:00PM
Apr-04-24 08:00AM
Mar-26-24 07:30AM
Mar-11-24 09:55AM
Mar-08-24 12:00PM
Mar-06-24 08:00AM
Mar-05-24 08:00AM
Feb-27-24 03:30AM
Feb-23-24 09:55AM
Feb-08-24 08:42AM
08:00AM
Jan-22-24 10:54AM
Jan-16-24 03:59AM
08:00AM
Loading…
Dec-28-23 08:00AM
Dec-05-23 07:32AM
07:10AM
07:00AM
Nov-13-23 09:55AM
Nov-08-23 09:10AM
Nov-07-23 08:00AM
Nov-03-23 07:30PM
Oct-17-23 03:00AM
Sep-19-23 04:01PM
08:00AM
Sep-14-23 01:23PM
Aug-03-23 08:00AM
Aug-01-23 08:00AM
Jul-31-23 04:01PM
Jul-28-23 03:57PM
Jul-20-23 08:00AM
Jun-06-23 10:00AM
Jun-05-23 08:00AM
Jun-03-23 02:15PM
Jun-01-23 04:01PM
May-25-23 05:00PM
May-18-23 08:00AM
May-17-23 10:02AM
May-09-23 08:00AM
Mar-31-23 09:35AM
Mar-08-23 08:00AM
Feb-24-23 09:35AM
Feb-09-23 08:50AM
08:00AM
Feb-07-23 08:00AM
Jan-06-23 09:55AM
09:04AM
08:50AM
Jan-05-23 05:44AM
(American City Business Journals)
Jan-04-23 08:05AM
08:00AM
Jan-03-23 08:00AM
Dec-14-22 10:46AM
Dec-12-22 02:36PM
Dec-08-22 09:04PM
Dec-07-22 04:04PM
10:05AM
07:00AM
06:30AM
Nov-23-22 08:00AM
Nov-22-22 08:00AM
Nov-03-22 08:00AM
Nov-02-22 04:01PM
Oct-14-22 01:52PM
Oct-07-22 08:00AM
Aug-24-22 07:58AM
Aug-06-22 09:36AM
Aug-04-22 08:00AM
Aug-01-22 04:01PM
Jun-03-22 08:00AM
Jun-02-22 08:00AM
May-30-22 06:42AM
May-26-22 05:15PM
May-19-22 08:00AM
May-03-22 08:55AM
Apr-14-22 01:35PM
Mar-30-22 07:00AM
Mar-21-22 08:00AM
Feb-11-22 08:00AM
Feb-03-22 08:00AM
Jan-31-22 04:01PM
Jan-10-22 07:00AM
Jan-04-22 08:00AM
Dec-17-21 09:35AM
Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Hill Emily Luisa Chief Financial Officer Aug 16 '24 Sale 10.18 8,938 90,989 101,057 Aug 19 08:00 PM Xynos Konstantinos Chief Medical Officer Jun 07 '24 Sale 7.50 15,881 119,108 117,131 Jun 10 08:30 PM Sarchi Christopher Chief Commercial Officer May 16 '24 Sale 6.47 2,218 14,350 92,252 May 20 08:06 PM Schwendenman Andrew Chief Accounting Officer May 16 '24 Sale 6.47 2,298 14,868 38,238 May 20 08:06 PM Love Colin Chief Operating Officer May 16 '24 Sale 6.47 17,615 113,969 777,345 May 20 08:05 PM Astley-Sparke Philip Executive Chairman May 16 '24 Sale 6.47 37,928 245,394 1,487,350 May 20 08:04 PM Coffin Robert Director May 16 '24 Sale 6.47 11,464 74,172 1,821,872 May 20 08:02 PM Patel Sushil Chief Executive Officer May 16 '24 Sale 6.47 20,194 130,655 212,014 May 20 08:01 PM Xynos Konstantinos Chief Medical Officer May 16 '24 Sale 6.47 6,367 41,194 133,012 May 20 08:00 PM Xynos Konstantinos Chief Medical Officer Nov 16 '23 Sale 10.92 7,313 79,858 112,714 Nov 17 08:01 PM Sarchi Christopher Chief Commercial Officer Nov 16 '23 Sale 10.92 5,255 57,385 72,245 Nov 17 08:00 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite